Screener
Amneal Pharmaceuticals, Inc. AMRX Specialty — Other Operating Income
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherOperatingIncomeExpenseNet.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Three Months Ended June 30, 2026 | Affordable Medicines (1) | Specialty | Av KARE | Corporateand Other | Total Company |
|---|---|---|---|---|---|
| Selling, general and administrative | 42,367 | 40,095 | 16,913 | 49,347 | 148,722 |
| Research and development | 33,023 | 5,994 | — | — | 39,017 |
| Intellectual property legal development expenses | 2,002 | 85 | — | — | 2,087 |
| Acquisition costs | — | — | — | 7,600 | 7,600 |
| Restructuring and other charges | — | — | — | 554 | 554 |
| Charges related to legal matters, net | 8,057 | — | — | — | 8,057 |
| Other operating income | (1,298) | — | — | — | (1,298) |
| Operating income (loss) | $123,078 | $54,856 | $9,336 | $(57,501) | $129,769 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s specialty — other operating income?
- Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — other operating income of $0 in Q2 2026.
- What does specialty — other operating income mean?
- Captures miscellaneous operating income or expenses that do not fit into standard categories like cost of goods sold or R&D. It provides visibility into peripheral business activities and non-core operational fluctuations within the specialty segment.
Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — other operating income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude